View virtual poster presentations and downloadable slides covering the most up-to-date clinical trial data from the 2019 Annual Neuroendocrine Cancer Meeting in Barcelona.
Mar 13, 2019
Mar 13, 2020
Abstract #H14: Development of a New and Improved Delivery System (DS) for Lanreotide Autogel/ Depot (LAN) to Further Enhance Patient Care
Featured Expert: Wendy Martin, RN, MSc
Abstract #I01: Treatment Strategies Derived from Comprehensive Genomic and Transcriptomic Analysis in Patients with Advanced-Stage Neuroendocrine Neoplasms: Results from the MASTER Trial of the German Cancer Consortium
Featured Expert: Leonidas Apostolidis, MD
Abstract #I03: Efficacy and Safety Analyses of the TALENT Trial (GETNE 1509): A Phase II Study of Lenvatinib in Patients (pts) with Advanced G1/G2 Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors
Featured Expert: Jaume Capdevila, MD, PhD
Abstract #J07: Long-Term Treatment with Telotristat Ethyl (TE) in Patients with Carcinoid Syndrome (CS) Symptoms: Results from TELEPATH Study
Featured Expert: Dieter Hörsch, MD, PhD
Abstract #M03: Population Data from Atlant, Phase 2 Study Combination Trial between Long Acting Somatostatin Analogue (SSA) Lanreotide (LAN) and Temozolomide (TMZ) in Progressive Thoracic (Lung/Thymus) Well Differentiated NET (Carcinoid) (TNETS)
Featured Expert: Piero Ferolla, MD, PhD
Leonidas Apostolidis, MDUniversity Hospital Heidelberg
Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
Piero Ferolla, MD, PhDUniversity of Perugia
Dieter Hörsch, MD, PhDCenter for Neuroendocrine Tumors Bad Berka
Bad Berka, Germany
Wendy Martin, RN, MScKings College Hospital NHS Trust
London, United Kingdom
This educational activity is designed for medical oncologists, endocrinologists, gastroenterologists and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors (NETs).
Upon completion of this educational activity, participants should be able to:
- Describe recent findings on the contemporary use of somatostatin analog therapy in the management of NETs/neuroendocrine neoplasms (NENs)
- Assess clinical trial data describing the use of treatment options for carcinoid syndrome
This educational activity is supported by Ipsen.
Independent Medical Education (IME)
This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This educational activity is provided by prIME, a Medscape Oncology Company.
Disclosure of Relevant Financial Relationships
prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
[SPEAKER NAME 1] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
[SPEAKER NAME 2] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
[SPEAKER NAME 3] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
[SPEAKER NAME 4] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
[SPEAKER NAME 5] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.